Citations

Clear

371 citation(s) found for "Cho, B".

P112/92  The current diagnostic performance of MRI-based radiomics for glioma grading
Skogen, Karoline , Ugga, Lorenzo , Brinjikji, Waleed , Maria, Lucio De , Ponzio, Francesco , Agosti, Edoardo , Cho, Hwan-ho , Tsougos, Ioannis , Gasparini, Mauro , Panciani, Pier Paolo , Fontanella, Marco Maria

Mayo Clinic

Abstracts | August 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: A58.2-A58

10.1136/jnis-2023-esmint.142 Get It

P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
Poon, Michelle, Champion, Rebecca A., Guidez, Stéphanie , Alonso, Aránzazu Alonso, Jagadeesh, Deepa, Tucker, David , Cai, Jingxian, Oliveira, Carolina Leite De, Chaudhry, Aafia, Ambati, Srikanth, Taszner, Michał , Luminari, Stefano , Cho, Seok‐Goo , Novelli, Silvana , Gouill, Steven Le , Villasboas, José C. , Champion, Rebecca, Bachy, Emmanuel , Alonso, Aránzazu , Jagadeesh, Deepa , Merli, Michele , Zhu, Min , Mohamed, Hesham , Kim, Tae Min

Mayo Clinic

HemaSphere | August 8, 2023 | Volume: 7 | Issue: S3 | Pages: e214536e

10.1097/01.hs9.0000971228.21453.6e Get It

A Polygenic Risk Score for Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormalities
Peljto, Anna L. , Xu, Hanfei , Debban, Catherine L., Chen, Xianfeng , Menon, Aravind , Putman, Rachel K. , Saferali, Aabida , Nishino, Mizuki , Hatabu, Hiroto , Hobbs, Brian D. , McDermott, Gregory C , Sparks, Jeffrey A. , Allen, Richard J. , Raby, Benjamin A. , Chun, Sung , Silverman, Edwin K. , Zamora, Ana, Ortega, Victor E. , Bleecker, Eugene R. , Meyers, Deborah A. , Rotter, Jerome I. , Fingerlin, Tasha E. , Hunninghake, Gary M. , Peljto, Anna L , Menon, Aravind , Zamora, Ana C., Garcia, Christine K , Sparks, Jeffrey A , McDermott, Gregory , Rotter, Jerome I , Hobbs, Brian D , Allen, Richard J , Hunninghake, Gary M , Moll, Matthew , Kim, John S. , Ghosh, Auyon , Hecker, Julian , Wain, Louise V , Tobin, Martin D. , Barr, R. Graham , Kaner, Robert J. , Rich, Stephen S. , Manichaikul, Ani , Dupuis, Josée , O’Connor, George T. , Schwartz, David A. , Cho, Michael H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 31, 2023 | Volume: 208 | Issue: 7 | Pages: 791-801

10.1164/rccm.202212-2257oc | PMID 37523715 Get It

Abstract Rationale In addition to rare genetic variants and the MUC5B locus, common genetic variants contribute to idiopathic pulmonary fibrosis (IPF) risk. The predictive power of common variants outside the MUC5B locus for IPF and interstitial lung abnormalities (ILAs) is unknown. Objectives We tested the predictive value of IPF polygenic risk scores (PRSs) with and without the MUC5B region on IPF, ILA, and ILA progression. Methods We developed PRSs that included (PRS-M5B) and excluded (PRS-NO-M5B) the MUC5B region (500-kb window around rs35705950-T) using an IPF genome-wide association study. We assessed PRS associations with area under the receiver operating characteristic curve (AUC) metrics for IPF, ILA, and ILA progression. Measurements and Main Results We included 14,650 participants (1,970 IPF; 1,068 ILA) from six multi-ancestry population-based and case–control cohorts. In cases excluded from genome-wide association study, the PRS-M5B (odds ratio [OR] per SD of the score, 3.1; P = 7.1 × 10−95) and PRS-NO-M5B (OR per SD, 2.8; P = 2.5 × 10−87) were associated with IPF. Participants in the top PRS-NO-M5B quintile had ∼sevenfold odds for IPF compared with those in the first quintile. A clinical model predicted IPF (AUC, 0.61); rs35705950-T and PRS-NO-M5B demonstrated higher AUCs (0.73 and 0.7, respectively), and adding both genetic predictors to a clinical model yielded the highest performance (AUC, 0.81). The PRS-NO-M5B was associated with ILA (OR, 1.25) and ILA progression (OR, 1.16) in European ancestry participants. Conclusions A common genetic variant risk score complements the MUC5B variant to identify individuals at high risk of interstitial lung abnormalities and pulmonary fibrosis.
Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma
Castellino, Sharon M. , Giulino‐Roth, Lisa , Harker‐Murray, Paul , Cho, Steve , Hoppe, Bradford S. , Parsons, Susan K. , Kelly, Kara M. , Kahn, Justine M , Hoppe, Bradford S , K Parsons, Susan , Castellino, Sharon , Forlenza, Christopher J.

Mayo Clinic

Pediatric Blood & Cancer | July 28, 2023 | Volume: 70 | Issue: S6 | Pages: No page available

10.1002/pbc.30580 | PMID 37505794 Get It

AbstractThe goal of therapy in pediatric Hodgkin lymphoma (HL) is to maximize overall survival while minimizing the morbidity of curative therapy. Key findings from recent Children's Oncology Group (COG) trials include: (i) superior event‐free survival with the addition of brentuximab vedotin (Bv) in frontline regimens for high‐risk disease, (ii) successful reduction in myeloablative regimens with demonstrated safety and efficacy of Bv and checkpoint inhibitor therapy in relapsed disease, and (ii) the potential to select a population that can be salvaged after relapse without receiving a stem cell transplant. The COG HL committee will lead a National cancer Institute National Clinical Trials Network phase 3 trial to evaluate the combination of Bv/nivolumab in early‐stage disease. Ongoing advances in technology and blood biomarkers are increasing the ability to deliver biologically driven, personalized treatment for HL.
Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real‐world patient data repository
Farber, Harrison W. , Chakinala, Murali M. , Cho, Michelle, Frantz, Robert P. , Frick, Andrew , Lancaster, Lisa , Milligan, Scott , Oudiz, Ronald J. , Panjabi, Sumeet , Tsang, Yuen, Nathan, Steven D. , Frantz, Robert P , Oudiz, Ronald

Mayo Clinic

Pulmonary Circulation | July 7, 2023 | Volume: 13 | Issue: 3 | Pages: No page available

10.1002/pul2.12258 | PMID 37427090 Get It

AbstractPulmonary arterial hypertension (PAH) is a rare, life‐limiting disease. PAH registries provide real‐world data that complement clinical trial data and inform treatment decisions. The TRIO comprehensive, integrated patient data repository (TRIO CIPDR), is an innovative US repository capturing data on contemporary patients diagnosed with pulmonary hypertension and receiving US Food and Drug Administration‐approved PAH therapies. This repository uniquely combines clinical data from electronic medical records with the ability to track drug‐prescription and drug‐dispensing characteristics, and includes 946 adult patients with PAH (data collected January 2019 to December 2020) enrolled from nine representative US specialist tertiary care centers. Potentially eligible patients were identified based on dispensing data from specialty pharmacies. Hemodynamic and clinical data, as well as dispensing information on prescribed PAH medications, were provided by tertiary centers. At enrollment, 75% of patients were female, 67% were White, median age at PAH diagnosis was 53 years (median time from diagnosis to enrollment was 5 years), and 37% were obese. Comorbidity profiles were as expected for a PAH population, although the proportion with atrial fibrillation (34%) was higher than expected. Overall, 38% of patients had idiopathic PAH and 30% had connective tissue disease‐related PAH. Among 917 patients receiving PAH‐specific therapy, 40% were on monotherapy, 43% on dual therapy, and 17% on triple therapy. Longitudinal data from this repository will allow tracking of the PAH treatment journey in relation to clinical characteristics and outcomes.
PATTERNS OF PRESENTATION AND OUTCOMES IN STAGE IV HODGKIN LYMPHOMA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP (COG) AHOD1331 TRIAL
McCarten, Kathleen M. , Pei, Qinglin , Milgrom, Sarah A. , Belsky, Joseph L., Cho, S., Keller, Frank G. , Punnett, Angela , Kelly, Kara M. , Casey, Dana L. , Belsky, J., Hoppe, Bradford S. , Castellino, Sharon M.

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 69-69

10.1002/hon.3163_34 Get It

ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2
Cho, S. , Poon, Michelle, Champion, Rebecca, Guidez, Stéphanie , Jagadeesh, Deepa , Oliveira, Carolina Leite De, Chaudhry, A., Ambati, Srikanth, Kim, T. M., Novelli, Silvana , Luminari, Stefano , Taszner, Michał , Gouill, Steven Le , Villasboas, José C. , Bachy, Emmanuel , Alonso, Aránzazu , Merli, Michele , Tucker, David , Cai, James J. , Zhu, Min , Mohamed, Hesham , Kim, Tae Min

Mayo Clinic

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 121-122

10.1002/hon.3163_82 Get It

Exercise Capacity and Pulmonary Capacitance Are Attenuated in Patients with Nonalcoholic Steatohepatitis
Donkor, Joshua, Carlson, Alex R. , Ziegler, Briana, Johnston, Jessica I., Johnson, Bruce D. , Kim, Chul-Ho, Cho, Jinkyung , Kim, Chul-Ho

Mayo Clinic

The Korean Journal of Sports Medicine | June 1, 2023 | Volume: 41 | Issue: 2 | Pages: 107-110

10.5763/kjsm.2023.41.2.107 Get It

Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831
Hodgson, David C. , Lee, Inki , Pei, Qinglin , Wu, Yue , McCarten, Kathleen M. , Hoppe, Bradford S. , Roberts, Kenneth B. , Milgrom, Sarah A. , Kessel, Sandy, Cole, Peter D. , Kelly, Kara M. , Hodgson, David C , Milgrom, Sarah , Cole, Peter D , Hoppe, Bradford S , Hodgson, David , Cho, Steve Y.

Mayo Clinic

Pediatric Blood & Cancer | May 27, 2023 | Volume: 70 | Issue: 8 | Pages: No page available

10.1002/pbc.30452 | PMID 37243975 Get It

AbstractPurpose/objectiveWe compared the prognostic value of chest radiograph (CXR)‐ and computed tomography (CT)‐derived definition of large mediastinal adenopathy (LMA) in pediatric Hodgkin lymphoma (HL).Materials/methodsTotal 143 patients treated for stage IIIB/IVB HL on COG AHOD0831 were included in this study. Six definitions of LMA were investigated: (i) mediastinal mass ratio on CXR (MRCXR) > 1/3; (ii) mediastinal mass ratio on CT (MRCT) > 1/3; (iii) mediastinal mass volume on CT (MVCT) > 200 mL; (iv) normalized mediastinal mass volume (MVCT/thoracic diameter [TD]) > 1 mL/mm; (v) mediastinal mass diameter on CT (MDCT) > 10 cm; and (vi) normalized mediastinal mass diameter (MDCT/TD) > 1/3.ResultsMedian age at diagnosis was 15.8 years (range: 5.2–21.3 years). In patients with a slow early response (SER) to chemotherapy, MVCT > 200 mL, MDCT > 10 cm, and MDCT/TD > 1/3 were associated with worse relapse‐free survival (RFS) on MVA, while MRCXR > 1/3, MRCT > 1/3, and MVCT/TD > 1 mL/mm trended toward worse RFS; MDCT/TD was the most strongly prognostic for inferior RFS, with a hazard ratio of 6.41 for MDCT/TD > 1/3 versus ≤1/3 on MVA (p = .02).ConclusionLMA according to MVCT > 200 mL, MDCT > 10 cm, and MDCT/TD > 1/3 is associated with poor prognosis in advanced‐stage HL patients with SER. The normalized mediastinal diameter, MDCT/TD > 1/3 appears to be the strongest predictor of inferior RFS.